Health Care [ 4/12 ] | Biotechnology [ 21/75 ]
NASDAQ | Common Stock
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies.
The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.
It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies.
The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 25 | -0.11 Increased by +50.00% | -0.05 Decreased by -120.00% |
| Aug 14, 25 | -0.16 Increased by +33.33% | -0.10 Decreased by -60.00% |
| Jun 13, 25 | -0.18 Increased by +70.97% | -0.11 Decreased by -63.64% |
| Mar 11, 25 | -0.20 Increased by +68.75% | -0.26 Increased by +22.09% |
| Nov 9, 24 | -0.22 Increased by +63.93% | -0.25 Increased by +12.00% |
| Aug 8, 24 | -0.24 Increased by +65.71% | -0.23 Decreased by -4.35% |
| May 14, 24 | -0.62 Increased by +25.30% | -0.11 Decreased by -463.64% |
| Feb 7, 24 | -0.64 Increased by +21.95% | -0.64 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 19.07 M Increased by +742.51% | -16.29 M Decreased by -16.17% | Decreased by -85.42% Increased by +86.21% |
| Jun 30, 25 | 8.08 M Increased by +242.98% | -15.84 M Decreased by -13.78% | Decreased by -195.99% Increased by +66.83% |
| Mar 31, 25 | 2.93 M Increased by +0.96% | -13.27 M Increased by +22.89% | Decreased by -452.73% Increased by +23.63% |
| Dec 31, 24 | 1.72 M Increased by +N/A% | -13.09 M Increased by +21.82% | Decreased by -759.45% Decreased by N/A% |
| Sep 30, 24 | 2.26 M Increased by +N/A% | -14.02 M Increased by +27.56% | Decreased by -619.53% Decreased by N/A% |
| Jun 30, 24 | 2.36 M Increased by +N/A% | -13.93 M Increased by +34.52% | Decreased by -590.79% Decreased by N/A% |
| Mar 31, 24 | 2.90 M Increased by +N/A% | -17.20 M Increased by +20.96% | Decreased by -592.80% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -16.75 M Increased by +15.37% | Decreased by N/A% Decreased by N/A% |